Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Oct 4:347:f5762.
doi: 10.1136/bmj.f5762.

Efficacy of anti-inflammatory or antibiotic treatment in patients with non-complicated acute bronchitis and discoloured sputum: randomised placebo controlled trial

Affiliations
Randomized Controlled Trial

Efficacy of anti-inflammatory or antibiotic treatment in patients with non-complicated acute bronchitis and discoloured sputum: randomised placebo controlled trial

Carl Llor et al. BMJ. .

Abstract

Objective: To evaluate the efficacy of oral anti-inflammatory or antibiotic treatment compared with placebo in the resolution of cough in patients with uncomplicated acute bronchitis and discoloured sputum.

Design: Multicentre, parallel, single blinded placebo controlled, randomised clinical trial.

Setting: Nine primary care centres in Spain.

Participants: Adults aged 18 to 70 presenting symptoms associated with respiratory tract infection of less than one week's duration, with cough as the predominant symptom, the presence of discoloured sputum, and at least one other symptom of lower respiratory tract infection (dyspnoea, wheezing, chest discomfort, or chest pain).

Interventions: Patients were randomised to receive either ibuprofen 600 mg three times daily, amoxicillin-clavulanic acid 500 mg/125 mg three times daily, or placebo three times daily for 10 days. The duration of symptoms was measured with a diary card.

Main outcome measure: Number of days with frequent cough after the randomisation visit.

Results: 416 participants were randomised (136 to ibuprofen, 137 to antibiotic, and 143 to placebo) and 390 returned their symptom diaries fully completed. The median number of days with frequent cough was slightly lower among patients assigned to ibuprofen (9 days, 95% confidence interval 8 to 10 days) compared with those receiving amoxicillin-clavulanic acid (11 days, 10 to 12 days) or placebo (11 days, 8 to 14 days), albeit without statistically significant differences. Neither amoxicillin-clavulanic acid nor ibuprofen increased the probability of cough resolution (hazard ratio 1.03, 95% confidence interval 0.78 to 1.35 and 1.23, 0.93 to 1.61, respectively) compared with placebo. Adverse events were observed in 27 patients, and were more common in the antibiotic arm (12%) than ibuprofen or placebo arms (5% and 3%, respectively; P<0.01).

Conclusion: No significant differences were observed in the number of days with cough between patients with uncomplicated acute bronchitis and discoloured sputum treated with ibuprofen, amoxicillin-clavulanic acid, or placebo.

Trial registration: Current Controlled Trials ISRCTN07852892.

PubMed Disclaimer

Conflict of interest statement

Competing interests: CL receives research grants from the European Commission (Sixth and Seventh Programme Frameworks), Catalan Society of Family Medicine, and Instituto de Salud Carlos III (Spanish Ministry of Health). Dr. Moragas reports receiving research grants from the Spanish Society of Family Medicine, Fundació Jordi Gol i Gurina, and Instituto de Salud Carlos III (Spanish Ministry of Health). Dr. Miravitlles reports receiving: honoraria for lectures from Bayer-Schering, Boehringer Ingelheim, Pfizer, Nycomed, AstraZeneca, and Novartis, payment for the development of educational presentations from Bayer-Schering, serving on the advisory boards of Bayer-Schering, Boehringer Ingelheim, Pfizer, Nycomed, GlaxoSmithKline, Almirall, AstraZeneca, and Novartis; and receiving consulting fees from Bayer-Schering, Boehringer-Ingelheim, Pfizer, Nycomed, GlaxoSmithKline, Almirall, AstraZeneca, and Novartis. The other authors do not report disclosures.

Figures

None
Fig 1 Flow of patients through study
None
Fig 2 Kaplan-Meier survival analysis of days with frequent cough—that is, time (days) with cough from baseline visit until patient last scored ≥1 for both daytime and night time cough
None
Fig 3 Kaplan-Meier survival analysis of days with any symptom—that is, time (days) from baseline visit until patient last scored ≥1 in any of five items in symptom diary

Comment in

Similar articles

Cited by

References

    1. Macfarlane J, Holmes W, Gard P, Macfarlane R, Rose D, Weston V, et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 2001;56:109-14. - PMC - PubMed
    1. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al; Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect 2011;17(Suppl 6):E1-59. - PMC - PubMed
    1. Ashworth M, Charlton J, Ballard K, Latinovic R, Gulliford M. Variations in antibiotic prescribing and consultation rates for acute respiratory infection in UK general practices 1995-2000. Br J Gen Pract 2005;55:603-8. - PMC - PubMed
    1. Chalmers JD, Hill AT. Investigation of “non-responding” presumed lower respiratory tract infection in primary care. BMJ 2011;343:d5840. - PubMed
    1. Boivin G, Abed Y, Pelletier G, Ruel L, Moisan D, Côté S, et al. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 2002;186:1330-4. - PubMed

Publication types

MeSH terms

Substances

Associated data